Structure-Activity Relationships of Bacillus cereus and Bacillus anthracis Dihydrofolate Reductase: toward the Identification of New Potent Drug Leads
Open Access
- 1 October 2006
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 50 (10), 3435-3443
- https://doi.org/10.1128/aac.00386-06
Abstract
New and improved therapeutics are needed for Bacillus anthracis , the etiological agent of anthrax. To date, antimicrobial agents have not been developed against the well-validated target dihydrofolate reductase (DHFR). In order to address whether DHFR inhibitors could have potential use as clinical agents against Bacillus , 27 compounds were screened against this enzyme from Bacillus cereus , which is identical to the enzyme from B. anthracis at the active site. Several 2,4-diamino-5-deazapteridine compounds exhibit submicromolar 50% inhibitory concentrations (IC 50 s). Four of the inhibitors displaying potency in vitro were tested in vivo and showed a marked growth inhibition of B. cereus ; the most potent of these has MIC 50 and minimum bactericidal concentrations at which 50% are killed of 1.6 μg/ml and 0.09 μg/ml, respectively. In order to illustrate structure-activity relationships for the classes of inhibitors tested, each of the 27 inhibitors was docked into homology models of the B. cereus and B. anthracis DHFR proteins, allowing the development of a rationale for the inhibition profiles. A combination of favorable interactions with the diaminopyrimidine and substituted phenyl rings explains the low IC 50 values of potent inhibitors; steric interactions explain higher IC 50 values. These experiments show that DHFR is a reasonable antimicrobial target for Bacillus anthracis and that there is a class of inhibitors that possess sufficient potency and antibacterial activity to suggest further development.Keywords
This publication has 25 references indexed in Scilit:
- Functional Cloning of Bacillus anthracis Dihydrofolate Reductase and Confirmation of Natural Resistance to TrimethoprimAntimicrobial Agents and Chemotherapy, 2004
- Genome Differences That Distinguish Bacillus anthracis from Bacillus cereus and Bacillus thuringiensisApplied and Environmental Microbiology, 2003
- Further Studies on 2,4-Diamino-5-(2‘,5‘-disubstituted benzyl)pyrimidines as Potent and Selective Inhibitors of Dihydrofolate Reductases from Three Major Opportunistic Pathogens of AIDSJournal of Medicinal Chemistry, 2003
- FlexE: efficient molecular docking considering protein structure variationsJournal of Molecular Biology, 2001
- Multiple Mutations Modulate the Function of Dihydrofolate Reductase in Trimethoprim-Resistant Streptococcus pneumoniaeAntimicrobial Agents and Chemotherapy, 2001
- T-coffee: a novel method for fast and accurate multiple sequence alignment 1 1Edited by J. ThorntonJournal of Molecular Biology, 2000
- Synthesis of 2,4-Diaminopteridines with Bulky Lipophilic Groups at the 6-Position as Inhibitors of Pneumocystis carinii, Toxoplasma gondii, and Mammalian Dihydrofolate ReductasePteridines, 1997
- A single amino acid substitution in Staphylococcus aureus dihydrofolate reductase determines trimethoprim resistance 1 1 Edited by T.RichmondJournal of Molecular Biology, 1997
- Brominated trimetrexate analogues as inhibitors of pneumocystis carinii and toxoplasma gondii dihydrofolate reductaseJournal of Heterocyclic Chemistry, 1996
- Quinazolines. XIII. Synthesis of polycyclic 2,4-diaminopyrimidines from aromatic amine hydrochlorides and sodium dicyanamideThe Journal of Organic Chemistry, 1974